| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 05/25/2005 | EP1532147A1 Spirosubstituted piperidines as selective melanin concentrating hormone receptor antagonists for the treatment of obesity |
| 05/25/2005 | EP1532145A1 Pyrazole compositions useful as inhibitors of gsk-3 |
| 05/25/2005 | EP1531906A1 Novel screens to identify agents that modulate retinal blood vessel function and pericyte function and diagnostic and therapeutic application therefor |
| 05/25/2005 | EP1531904A1 Combination of an allosteric inhibitor of matrix metalloproteinase-13 with a selective inhibitor of cyclooxygenase-2 that is not celecoxib or valdecoxib |
| 05/25/2005 | EP1531869A2 Compositions and methods for treating cancer using maytansinoid cd44 antibody immunoconjugates and chemotherapeutic agents |
| 05/25/2005 | EP1531866A1 Pharmaceutical products and compositions comprising specific anticholinergic agents, beta-2 agonists and corticosteroids |
| 05/25/2005 | EP1531855A2 Treatment of bone disorders with skeletal anabolic drugs |
| 05/25/2005 | EP1531843A1 Method for treating cervical cancer |
| 05/25/2005 | EP1531842A2 Regulation of cell growth by muc1 |
| 05/25/2005 | EP1531837A1 Compositions and methods for the prophylaxis and treatment of aphthous ulcers and herpes simplex lesions |
| 05/25/2005 | EP1531831A1 Fosinopril formulation |
| 05/25/2005 | EP1531828A2 Methods of treating bacterial infections and diseases associated therewith |
| 05/25/2005 | EP1531827A2 Copper lowering treatment of inflammatory and fibrotic diseases |
| 05/25/2005 | EP1531823A2 Flavin n-oxides: new anti-cancer agents and pathogen eradication agents |
| 05/25/2005 | EP1531818A1 Topical treatment of skin diseases |
| 05/25/2005 | EP1531815A1 Glucokinase activators |
| 05/25/2005 | EP1531806A2 Use of thio-oxindole derivatives in treatment of hormone-related conditions |
| 05/25/2005 | EP1531805A1 Composition comprising a cholesterol absorption inhibitor, an hmg-coa reductase inhibitor and a stabilizing agent |
| 05/25/2005 | EP1531801A1 Combination of an allosteric inhibitor or matrix metalloproteinase-13 with a selective inhibitor of cyclooxygenase-2 that is not celecoxib or valdecoxib |
| 05/25/2005 | EP1531800A2 Stealth lipid nanocapsules, methods for the preparation thereof and use thereof as a carrier for active principle(s) |
| 05/25/2005 | EP1531799A1 Nanoparticulate formulations comprising hmg coa reductase inhibitor derivatives ("statins"), novel combinations thereof as well as manufacturing of these pharmaceutical compositions |
| 05/25/2005 | EP1531795A1 Formulations limiting spread of pulmonary infections |
| 05/25/2005 | EP1531792A2 Abuse-resistant opioid dosage form |
| 05/25/2005 | EP1531716A2 Methods for using adamts-12, an integrin and metalloprotease with thrombospondin motifs |
| 05/25/2005 | EP1531676A2 Compositions and methods for liver growth and liver protection |
| 05/25/2005 | EP1307594A4 Association of sim2 with cancer |
| 05/25/2005 | EP1286673B1 Ligands of integrin receptors |
| 05/25/2005 | EP1214059B1 Surface modified particulate compositions of biologically active substances |
| 05/25/2005 | EP1165058B1 Azalide antibiotics for the topical treatment or prevention of ocular infections |
| 05/25/2005 | EP1115434B1 Adhesive protein foam for surgical and/or therapeutic uses |
| 05/25/2005 | EP1056473B1 Targeted delivery of biologically active media |
| 05/25/2005 | EP1044023B1 A covalent conjugate of clozapine with a fatty acid and its use for treating schizophrenia |
| 05/25/2005 | EP0880362B1 Compositions comprising a cyclooxygenase-2 inhibitor and a leukotriene b 4 receptor antagonist |
| 05/25/2005 | EP0814796B1 Use of a r-nsaid in a protective composition for the treatment of colorectal cancer |
| 05/25/2005 | DE10359336A1 Use of potassium channel openers in synergistic combination with sodium channel inhibiting/influencing active compounds for treating pains accompanied by increase in muscle tone |
| 05/25/2005 | DE10359335A1 Kombinationen aus Kaliumkanalöffnern und Natriumkanalinhibitoren oder Natriumkanal beeinflussenden Wirkstoffen zur Behandlung von Schmerzzuständen Combinations of potassium channel openers and sodium channel inhibitors and sodium channel influencing agents for the treatment of pain |
| 05/25/2005 | CN1620499A Igamete recruitment and developmental competence in mammals by inhibiting the de novo sterol biosynthesis and/or promoting sterol efflux |
| 05/25/2005 | CN1620468A Novel anti-igf-ir antibodies and uses thereof |
| 05/25/2005 | CN1620467A Secreted protein |
| 05/25/2005 | CN1620457A Tetracyclic heterocompounds as estrogen receptor modulators |
| 05/25/2005 | CN1620453A Thiazolidinedione derivative and its use as antidiabetic |
| 05/25/2005 | CN1620430A 3-phenyl-2-arylalkylthiopropionic acid derivatives as selective agonists of PPAR-alpha |
| 05/25/2005 | CN1620423A Substituted phenypropionic acid derivatives as agonists to human peroxisome proliferator-activated receptor alpha (PPAR) |
| 05/25/2005 | CN1620422A Substituted phenypropionic acid derivatives as agonists to human peroxisome proliferator-activated receptor alpha (PPAR) |
| 05/25/2005 | CN1620421A Substituted alkyl diamine |
| 05/25/2005 | CN1620311A Therapeutic agent |
| 05/25/2005 | CN1620304A Prevention and treatment of oxidative stress disorders by glutathione and phase IIdetoxification enzymes |
| 05/25/2005 | CN1620301A Pharmaceutically acceptable phosphate-glycerol carrying bodies |
| 05/25/2005 | CN1620298A Tibolone in the treatment of complaints associated with the administration of drugs which prevent the synthesis of endogenous estrogen |
| 05/25/2005 | CN1620292A Broadspectrum heterocyclic substituted phenyl containing sulfonamide HIV protease inhibitors |
| 05/25/2005 | CN1620284A Dosage form with a core tablet of active ingredient sheathed in a compressed annular body of powder or granular material, and process and tool for producing it |
| 05/25/2005 | CN1620283A Dispersions for formulating slightly or poorly soluble active ingredients |
| 05/25/2005 | CN1620281A Formulation & dosage form for the controlled delivery of therapeutic agents |
| 05/25/2005 | CN1618789A Macrocyclic peptides active against the hepatitis C virus |
| 05/25/2005 | CN1203091C TGF (b) 1 inhibitor peptides |
| 05/25/2005 | CN1203072C Pyranoindoles for treating alaucoma |
| 05/25/2005 | CN1202865C Synergistic combination |
| 05/25/2005 | CN1202864C Use of CD40:CD154 binding interruptor to prevent counter adaptive immune responses, particularly graft rejection |
| 05/24/2005 | US6897349 Silver-containing compositions, devices and methods for making |
| 05/24/2005 | US6897236 Aminobenzophenones as inhibitors of IL-1β and TNF-α |
| 05/24/2005 | US6897235 Compositions useful for the treatment of pathologies responding to the activation of PPAR-γ receptor |
| 05/24/2005 | US6897229 Use of PDE4 inhibitor N-(3,5-dichloropyrid-4-yl)-3-cyclopropylmethoxy-4-difluoromethoxybenzamide, salts or its N-oxide with PDE3 inhibitor for treatment of obstructions of bronchi |
| 05/24/2005 | US6897206 Combinations for the treatment of inflammatory disorders |
| 05/24/2005 | US6897202 Spray dry products, comprising glucose, maltotriose, oligosaccharides or polysaccharides of glucose; use in foods, cosmetics, and pharmaceuticals, soluble in aqueous solvents |
| 05/24/2005 | US6897034 Antitumor agents; drug immobilized to oligopeptide; complexing; testing, calibration of complex to see if capable of being split enzyme; drug design |
| 05/24/2005 | US6896907 Use of bioactive fraction from cow urine distillate (‘go-mutra’) as a bio-enhancer of anti-infective, anti-cancer agents and nutrients |
| 05/24/2005 | US6896904 Multilayer crosslinking porous structure; prosthetic bones, drug delivery |
| 05/24/2005 | US6896899 Pharmaceutical preparations of glutathione and methods of administration thereof |
| 05/24/2005 | US6896898 Analgesics; antiinflammatory agents; sustained release |
| 05/24/2005 | US6896891 Non-systemic control of parasites |
| 05/24/2005 | US6896885 Combined use of anti-cytokine antibodies or antagonists and anti-CD20 for treatment of B cell lymphoma |
| 05/24/2005 | US6896879 Method of pre-sensitizing cancer prior to treatment with radiation and/or chemotherapy and a novel cytokine mixture |
| 05/24/2005 | US6896652 Cardiac disease treatment and device |
| 05/24/2005 | CA2432405C Water-free skin care formulations comprising micronized urea and method of manufacturing the same |
| 05/24/2005 | CA2354237C A pharmaceutical composition for the treatment of attention deficit hyperactivity disorder (adhd) |
| 05/24/2005 | CA2151476C Use of cyclooxygenase inhibitors for the manufacture of a medicament for enhancing uterine blood perfusion |
| 05/24/2005 | CA2109259C Prodrugs, their preparation and use as pharmaceuticals |
| 05/21/2005 | CA2488066A1 Treatment of spondylarthropathies |
| 05/19/2005 | WO2005044302A1 Selective erbb2 inhibitor/anti-erbb antibody combinations in the treatment of cancer |
| 05/19/2005 | WO2005044287A1 Disinfecting composition and methods of making and using same |
| 05/19/2005 | WO2005044275A1 Use |
| 05/19/2005 | WO2005044254A1 Salts of pharmacologically active compounds |
| 05/19/2005 | WO2005044248A1 Use of proglumide and tramadol in the treatment of pain |
| 05/19/2005 | WO2005044246A2 Controlled release analgesic suspensions |
| 05/19/2005 | WO2005044245A1 USES OF ADENOSINE A2a RECEPTOR ANTAGONISTS |
| 05/19/2005 | WO2005044243A2 Transdermal analgesic systems having reduced abuse potential |
| 05/19/2005 | WO2005044200A2 Methods and compositions for treating mcp-1 related pathologies |
| 05/19/2005 | WO2005044192A2 Triazole compounds and uses related thereto |
| 05/19/2005 | WO2005044182A2 Compositions of botanical extracts for cancer therapy |
| 05/19/2005 | WO2005025501A3 Co-administration of polysaccharide with a chemotherapeutic agent for the treatment of cancer |
| 05/19/2005 | WO2005020879A3 Compositions for treating pathologies that necessitate suppression of gastric acid secretion |
| 05/19/2005 | WO2005013900A3 Method and composition for treating peridontal disease |
| 05/19/2005 | WO2005011614A8 Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anti-ige antibody for treatment of asthma or chronic obstructive pulmonary disease |
| 05/19/2005 | WO2005000211A3 Method for treating diseases using hsp90-inhibiting agents in combination with platinum coordination complexes |
| 05/19/2005 | WO2004108083A3 Methods for the selective treatment of tumors by calcium-mediated induction of apoptosis |
| 05/19/2005 | WO2004106378A3 Method of treating corneal transplant rejection by using vegf antagonists |
| 05/19/2005 | WO2004091531A3 Methods and devices for epithelial protection during photodynamic therapy |
| 05/19/2005 | WO2004064719A3 Synergistic compositions and methods for potentiating anti-oxidative activity |
| 05/19/2005 | WO2004062626A3 Composition and method for treating age-related disorders |
| 05/19/2005 | WO2004052292A3 Histone deacetylase inhibitor enhancement of trail-induced apoptosis |